Filing Details

Accession Number:
0001209191-21-071176
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-12-23 19:02:53
Reporting Period:
2021-12-21
Accepted Time:
2021-12-23 19:02:53
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1567514 Intra-Cellular Therapies Inc. ITCI () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1521548 Michael Halstead C/O Intra-Cellular Therapies, Inc.
430 East 29Th Street
New York NY 10016
Evp And General Counsel No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-12-21 25,000 $13.86 25,000 No 4 M Direct
Common Stock Acquisiton 2021-12-21 88,146 $17.57 113,146 No 4 M Direct
Common Stock Acquisiton 2021-12-21 63,717 $15.73 176,863 No 4 M Direct
Common Stock Disposition 2021-12-21 22,620 $48.62 154,243 No 4 S Direct
Common Stock Disposition 2021-12-21 104,775 $47.84 49,468 No 4 S Direct
Common Stock Disposition 2021-12-21 36,434 $46.87 13,034 No 4 S Direct
Common Stock Disposition 2021-12-21 8,690 $45.74 4,344 No 4 S Direct
Common Stock Disposition 2021-12-21 4,344 $44.87 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2021-12-21 25,000 $0.00 25,000 $13.86
Common Stock Stock Option (right to buy) Disposition 2021-12-21 88,146 $0.00 88,146 $17.57
Common Stock Stock Option (right to buy) Disposition 2021-12-21 63,717 $0.00 63,717 $15.73
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2024-07-29 No 4 M Direct
0 2025-01-02 No 4 M Direct
0 2027-01-03 No 4 M Direct
Footnotes
  1. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.30 to $49.27, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.28 to $48.27, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.29 to $47.27, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.25 to $46.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
  6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.25 to $45.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
  7. All shares underlying this option have vested.